immunogenicity – Medxy AI

Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial

By MedXY 12/01/2025

A multicentre phase 1 trial in healthy US adults found nOPV1 and nOPV3 were well tolerated and induced robust homotypic neutralising antibody responses with shedding profiles similar to Sabin monovalent OPV, supporting progression to phase 2 studies.

Infectious Diseases news Pediatrics

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal

By MedXY 11/30/2025

A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.

Infectious Diseases news Public Health

Immunogenicity and HPV Infection After One, Two, and Three Doses of Quadrivalent HPV Vaccine in Indian Girls: A Multicentre Prospective Cohort Study

By MedXY 11/24/2025

This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.

Infectious Diseases news Public Health

A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda

By MedXY 11/23/2025

In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation of the 5×10^10-particle dose.

Infectious Diseases news Public Health

rVSVΔG‑LASV‑GPC Lassa Vaccine Shows Broad Immunogenicity and Acceptable Safety in Phase 1 Trial

By MedXY 11/10/2025

A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages.

Infectious Diseases news Public Health

Breakthrough in Enteric Fever Prevention: Efficacy and Safety of the Novel Salmonella Paratyphi A Vaccine CVD 1902

By MedXY 10/31/2025

A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.

Infectious Diseases news Respiratory Specialties

Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study

By MedXY 10/04/2025

This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting vaccination benefits amidst immunocompromised risks.

Pediatrics Public Health Specialties

Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers

By MedXY 08/28/2025

This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.

Clinical Updates HIV/AIDS Infectious Diseases news Specialties

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY 08/05/2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Clinical Updates news Pediatrics Respiratory Specialties

Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia

By MedXY 08/02/2025

A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.